In partnership with Synergy Enterprises, Inc., Lexicon & Line will support DEA prevention outreach and community ...

Lexicon has installed a new advanced robotics welding line at its Prospect Steel division in Blytheville, making the company ...

Three weeks after taking over as CEO of Lexicon Pharmaceuticals back in 2024, Michael Exton suggested the company close its ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to market open. Management will conduct a ...

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) for type 1 and type 2 diabetes after the ...

Q1 2026 Management View “We began this year with an ambitious set of 2026 objectives, which are to: firstly, advance our late-stage regulatory programs, both of which have major potential milestones ...

It’s been a winding road full of potholes, but Lexicon Pharmaceuticals has finally reached its destination, gaining an FDA approval for Inpefa (sotagliflozin). The once-daily pill becomes the first ...

THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S.

For the quarter, revenue was "negligible," similar to that of Q4 2020. This is not unusual for a clinical-stage biotech like Lexicon, which as a pre-commercial business has no products yet on the ...

An explosion in data volumes, proliferation of platforms, and evolving regulatory requirements has made effective monitoring of employee communications much more difficult. The remote and hybrid ...